Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells

Cancer Science

Volumn 101, Issue 9, 2010, Pages 2033-2038

  Feng, Yin Hsun ^a,b   Tsao, Chao Jung ^b   Wu, Chao Liang ^a   Chang, Jan Gowth ^c   Lu, Pei Jung ^a   Yeh, Kun Tu ^d   Shieh, Gia Shing ^a   Shiau, Ai Li ^a,e   Lee, Jeng Chang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SPROUTY2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COLONIC NEOPLASMS; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955942766     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01637.x     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-49.
2. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009, 60:207-19.
3. Wells A. EGF receptor. Int J Biochem Cell Biol 1999, 31:637-43.
4. Galizia G, Lieto E, Ferraraccio F. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006, 13:823-35.
5. Jones HE, Goddard L, Gee JM. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814.
6. Ranson M, Mansoor W, Jayson G. ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther 2002, 2:161-8.
7. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006, 12:7242-51.
8. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-39.
9. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005, 11:7480-9.
10. Zampino MG, Magni E, Santoro L. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib? Cancer Chemother Pharmacol 2008, 63:139-48.
11. Lievre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-5.
12. Lievre A, Bachet JB, Boige V. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-9.
13. Frattini M, Saletti P, Romagnani E. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-45.
14. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92:253-63.
15. Wong ES, Fong CW, Lim J. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J 2002, 21:4796-808.
16. Haglund K, Schmidt MH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep 2005, 6:635-41.
17. Kim HJ, Taylor LJ, Bar-Sagi D. Spatial regulation of EGFR signaling by Sprouty2. Curr Biol 2007, 17:455-61.
18. Lee CC, Putnam AJ, Miranti CK. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004, 23:5193-202.
19. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Hum Genet 2007, 54:12.10.1-12.10.24.
20. Tarnawski AS, Pai R, Tanigawa T, Matysiak-Budnik T, Ahluwalia A. PTEN silencing reverses aging-related impairment of angiogenesis in microvascular endothelial cells. Biochem Biophys Res Commun 2010, 394:291-6.
21. Colquhoun AJ, McHugh LA, Tulchinsky E, Kriajevska M, Mellon JK. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. J Radiat Res (Tokyo) 2007, 48:351-60.
22. Tonra JR, Deevi DS, Corcoran E. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197-207.
23. Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-57.
24. Zhu CQ, da Cunha Santos G, Ding K. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-75.
25. Mackenzie MJ, Hirte HW, Glenwood G. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005, 23:165-70.
26. Ciardiello F, Caputo R, Bianco R. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053-63.
27. Paez JG, Janne PA, Lee JC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-500.
28. Nagahara H, Mimori K, Ohta M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005, 11:1368-71.
29. Lo TL, Yusoff P, Fong CW. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004, 64:6127-36.
30. Sutterluty H, Mayer CE, Setinek U. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 2007, 5:509-20.
31. Fritzsche S, Kenzelmann M, Hoffmann MJ. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 2006, 13:839-49.
32. Fong CW, Chua MS, McKie AB. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006, 66:2048-58.
33. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006, 281:4816-22.
34. Douillard JY, Shepherd FA, Hirsh V. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-52.
35. Jackman DM, Miller VA, Cioffredi LA. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-73.
36. Kokubo Y, Gemma A, Noro R. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005, 92:1711-9.
37. Noro R, Gemma A, Miyanaga A. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 2007, 31:1157-63.
38. Chang YS, Yeh KT, Chang TJ. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009, 9:179.
39. Lin SY, Chen PH, Wang CK. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Pathol 1993, 100:686-9.